Neuracle Science Co., Ltd.

Snu Rdb Foundation

Hanwha Advanced Materials Corporation

Neuracle Sceince, Inc.

Jong Ik Hwang

Jae Young Seong

Eun Bee Cho

Woong Sun

Won-Ki Kim

Junho Chung

Bongcheol Kim

Jaeseok Yang

Junyeong Jin

Jee Youn Lee

Goo Jang

Byeong Chun Lee

Curie Ahn

Tae Young Yune

Dae Kee Kwon

Jung Taek Kang

Jae Seok Yang

Bum Rae Cho

Ok Jae Koo

Sol Park

Byoung Gon Moon

The present invention relates to the pharmaceutical use of FAM19A5 involved in regulating gliogenesis, and more specifically, to the use of FAM19A5 in the prevention, diagnosis, or treatment of central nervous system injuries, degenerative brain diseases, or central nervous system diseases, FAM19A5 being spread in the neural stem cells in vertebrates and regulating gliogenesis.

Pharmaceutical use of FAM19A5 involved in regulating gliogenesis

The present disclosure provides antibodies that specifically bind to human FAM19A5 and compositions comprising such antibodies. In a specific aspect, the antibodies specifically bind to human FAM19A5 and modulate FAM19A5 activity, e.g., inhibit, suppress, reduce, or reverse the onset of reactive gliosis and/or excessive proliferation of reactive astrocytes, utilizing such antibodies. The present disclosure also provides methods for treating disorders, such as central nervous system damage, a degenerative brain disorder, or a neuropathic pain, by administering an antibody that specifically binds to human FAM19A5.

Anti-family with sequence similarity 19, member A5 antibodies and method of use thereof

The present invention relates to a transgenic pig that expresses sTNFR1-Fc, wherein a gene encoding sTNFR1-Fc, which is a fusion protein of the extracellular domain of human soluble tumor necrosis factor receptor (sTNFR1) and an immunoglobulin Fc region, is introduced; a method for preparing the same; an organ isolated from the transgenic pig; a somatic donor cell line inserted with sTNFR1-Fc gene; a method for preparing a blood sample comprising sTNFR1-Fc; and a method for preparing human sTNFR1-Fc from the blood sample of the transgenic pig. As the transgenic pig can suppress immune response and inflammatory response by secreting an inhibitory substance that suppresses the activity of TNF-&#x3b1; in blood, it can be effectively used for xenograft. Furthermore, since the transgenic pig has a blood type O, it can be transplanted for suppressing inflammatory response, regardless of a blood type of recipient.

Transgenic pig expressing sTNFR1-Fc genes and the uses thereof

The present invention relates to a method for producing a transgenic pig in which immune rejection response is inhibited, and in which human HO-1 genes and TNFR1-Fe fusion genes are simultaneously expressed. The present invention also relates to a transgenic pig for organ transplantation, which is produced by the method, and in which immune rejection response is inhibited. The present invention also relates to a somatic-cell-donating cell strain for producing the transgenic pig, and to a method for producing organs, from the transgenic pig, in which the immune rejection response is inhibited.

Transgenic pig in which HO-1 and TNFR1-Fc are simultaneously expressed, and method for producing same

Growing community of inventors

Seoul, South Korea

Jong Ik Hwang